Adverse Event Reporting and Field Safety Corrective Action in Myanmar

1. Key takeaways

Myanmar’s post-market safety obligations are carried by two channels: adverse event (AE) reporting and field safety corrective action (FSCA), with manufacturers and importers as the responsible subjects. Together with active market sampling conducted every 2 months, the two channels form the post-market surveillance system. The division of labour is deliberate: sampling watches the shelf, while AE reporting and FSCA watch real-world use, and only the two passive channels depend on action taken by the companies themselves.

GRZAN note: AE reporting and FSCA are two mechanisms with different functions. The former is information transmission, reporting adverse events that have already occurred to the competent authority; the latter is risk control, taking corrective measures at the distribution and use stages. Companies must establish separate processes for the two, and neither can substitute for the other. A process that folds both into a single workflow tends to stall at exactly the point where the two diverge, namely after the information has been reported but before the corrective action has been decided, executed and verified in the field.

2. Legal basis

The table below summarises the official source of the obligation, the two monitoring layers, the reporting form and the structural context of import management. Read together, the rows show that AE reporting and FSCA are anchored in the same notification that establishes proactive sampling, so the passive duties cannot be separated from the system the authority already operates.

3. Expert insights

Insight 1: AE reporting is the information channel; FSCA is the disposal channel. The former answers whether the competent authority is informed; the latter answers whether the risk is under control. Conflating them produces a common failure mode in which a company files the report and considers the matter closed, while the affected devices remain in distribution. Each channel has its own trigger, its own actions and its own closure condition, and each must be tracked to its own completion. Separating the two in the procedure documents is the first step; separating them in daily practice is what the drills are for.

Insight 2: the responsible subjects are manufacturers and importers at both ends. This connects with the authorised representative system: foreign manufacturers perform the obligation through the local entity. In practice this means the authorised representative agreement must specify how event information reaches the manufacturer, how decisions are made, and how reports and corrective actions are submitted to the authority, because a chain with undefined links fails at the first real event. Clarity on paper before the event is what prevents improvisation during it.

Insight 3: proactive sampling and passive reporting form a cross-validation pair. The authority can compare market sampling results with the company’s reporting records to identify under-reporting. The comparison is structural, not discretionary: any finding that surfaces through sampling but was never reported is an obvious signal, and the company should assume the signal will be read. Internal reconciliation between complaint data, distribution data and sampling exposure is therefore part of routine compliance, not an emergency measure.

Insight 4: high-risk devices involve clinical professionals in supervision. This indicates a higher intensity of supervision for high-risk products. Companies supplying such devices must prepare stronger technical support resources, so that questions about clinical use conditions, adverse event causality or corrective measures can be answered with documentation rather than with assurances. The preparation is not only for the authority’s benefit: the same material shortens internal investigations, because the evidence needed to explain an event already exists in an organised form.

Insight 5: post-market obligations are a component of the three-step structure, not an add-on. Import management comprises pre-market, post-market and inter-agency collaboration as one architecture. Companies should therefore plan vigilance capability at the same time as they design their market entry strategy, not after registration has been granted, because retrofitting a vigilance system into an organisation built only for submission is slower and more error-prone than building it in from the start.

4. Practical recommendations

• Establish two separate processes for AE reporting and FSCA. Define the trigger conditions and the responsible person for each, so the information channel and the disposal channel never blur into one.
• Ensure the reporting channel reaches the competent authority without obstruction. Submit through the local authorised representative, and test the route before a real event forces the test; a channel that has never carried a report has never been proven to work.
• Build an internal problem ledger and link it to batch records. The linkage makes cross-verification straightforward when sampling results or distribution data are compared against reports, and it turns every past event into retrievable evidence rather than scattered correspondence.
• Allocate clinical technical support resources for high-risk products. Keep them available to answer collaborative supervision on clinical use conditions and event causality.
• Drill recall and corrective action processes periodically. Exercises verify that the system works end to end, from detection through decision to field execution and record closure.

5. Verification checklist

• □ An AE reporting process has been established
• □ An FSCA disposal process has been established
• □ The reporting channel through the local authorised representative to the competent authority has been confirmed
• □ An internal problem ledger linked to batch records has been established
• □ Clinical technical support resources for high-risk products have been allocated
• □ Recall and corrective action processes have been drilled periodically
• □ The items have been incorporated into the registration ledger

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com